We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.25 | -0.51% | 48.42 | 48.15 | 48.63 | 48.76 | 48.3451 | 48.39 | 1,273,831 | 00:33:13 |
From May 2019 to May 2024
By Inti Landauro
PARIS--French pharmaceutical giant Sanofi SA (SAN.FR) on Monday said it will resubmit in the second quarter an application to the U.S. Food and Drug Administration for its multiple sclerosis treatment Lemtrada, which received a negative review in November last year.
Genzyme, the unit of Paris-listed Sanofi which develops Lemtrada--also known as alemtuzumab--will resend an application to the FDA to address all the issues raised by the agency.
Genzyme has decided to resubmit the application instead of appealing the FDA decision as previously announced.
Write to Inti Landauro at inti.landauro@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
